Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLIO: Bayesian Estimator for Iohexol Clearance
NCT05136963Phase 1Not yet recruiting
- Sponsor
- CHU Saint-Etienne
- Start
- Jun 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iohexol, sponsored by CHU Saint-Etienne. Primary endpoint: Iohexol pharmacokinetic calculated with Bayesian estimator and with classic method at 12 hours. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
iohexol
Beyond the preview
Go deeper on NCT05136963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05136963.